Eli Lilly's Alzheimer's drug Kisunla, recently approved by the FDA, offers hope for patients with early symptomatic Alzheimer's disease. The drug, which slows cognitive and functional decline by 35 percent, targets the sticky plaque amyloid beta in the brain associated with the disease. It joins only one other drug, Leqembi, on the market for modifying the underlying disease. While the drug faces controversy due to complications like ARIA, experts believe its benefits outweigh risks. Eli Lilly plans to launch trials to test if Kisunla can prevent Alzheimer's in asymptomatic patients by clearing amyloid. The drug's cost, estimated at $32,000 per year, may be covered by Medicare for certain patients. Despite the drug not being a cure, like previous Alzheimer drugs, it offers a promising advancement in modifying the disease's progression.